Abstract: The present invention can synthesize lobaric acid and four analogues thereof, which are five phenolic lichen metabolites isolated from an extract of the Antarctic lichen Stereocaulon alpinum and selectively inhibit PTP1B, by a simple, economic and efficient chemical synthesis method.

Abstract: The present invention can synthesize lobaric acid and four analogues thereof, which are five phenolic lichen metabolites isolated from an extract of the Antarctic lichen Stereocaulon alpinum and selectively inhibit PTP1B, by a simple, economic and efficient chemical synthesis method.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating inflammatory diseases and a food for preventing or alleviating inflammatory diseases, both of which contain curvularin-type metabolites as an active ingredient and, more specifically to a pharmaceutical composition for preventing or treating inflammatory diseases and a food for preventing or alleviating inflammatory diseases, both of which contain, as an active ingredient, marine fungus Penicillium sp. SF-5859-derived curvularin-type metabolites. A pharmaceutical composition, according to the present invention, for preventing or treating inflammatory diseases, containing curvularin-type metabolites derived from marine fungus Penicillium sp. SF-5859 (KCTC 13354 BP) inhibits the production of proinflammatory cytokines and mediators, thereby being effectively usable for the prevention or treatment of inflammatory diseases.

Abstract: The present invention relates to an exopolysaccharide derived from Pseudoalteromonas sp. strain CY01 (KCTC 12867BP) which is a novel strain living in the polar regions, and to a composition for cryoprotection of cells, which contains the exopolysaccharide. The exopolysaccharide of the present invention has an excellent ability to cryoprotect cells, and shows no cytotoxicity. Thus, the inventive exopolysaccharide can substitute for conventional cryoprotective agents that show cytotoxicity when used at high concentrations.

Abstract: The present disclosure provides a method of purifying pharmaceutical compositions consisting essentially of STAT3 inhibitors from a mixture of compounds, pharmaceutical compositions comprising STAT3 inhibitors used to inhibit STAT3 in tumor cells, and certain pharmaceutically acceptable salts thereof, and methods of use.

Abstract: The present invention relates to an exopolysaccharide derived from Pseudoalteromonas sp. strain CY01 (KCTC 12867BP) which is a novel strain living in the polar regions, and to a composition for cryoprotection of cells, which contains the exopolysaccharide. The exopolysaccharide of the present invention has an excellent ability to cryoprotect cells, and shows no cytotoxicity. Thus, the inventive exopolysaccharide can substitute for conventional cryoprotective agents that show cytotoxicity when used at high concentrations.

Abstract: The present disclosure provides a method of purifying pharmaceutical compositions consisting essentially of STAT3 inhibitors from a mixture of compounds, pharmaceutical compositions comprising STAT3 inhibitors used to inhibit STAT3 in tumor cells, and certain pharmaceutically acceptable salts thereof, and methods of use.

Abstract: The present invention relates to a composition comprising an extract of Anemarrhena asphodeloides Bunge or the compounds isolated from the same, as an active ingredient. In particular, the extract and compounds have the excellent inhibitory effects on adipocyte differentiation, and thus can be used in a pharmaceutical composition and functional food for the prevention and treatment of lipid metabolism disorders.

Abstract: The present invention relates to a composition comprising an extract of Anemarrhena asphodeloides Bunge or the compounds isolated from the same, as an active ingredient. In particular, the extract and compounds have the excellent inhibitory effects on adipocyte differentiation, and thus can be used in a pharmaceutical composition and functional food for the prevention and treatment of lipid metabolism disorders.

Abstract: Provided are a novel transition metal complex where a monocyclopentadienyl ligand to which an amido or alcoxy group is introduced is coordinated, a method of synthesizing the same, and olefin polymerization using the transition metal complex. Compared to a conventional transition metal complex having a silicon bridge and an oxido ligand, the transition metal complex has a phenylene bridge, so that a monomer easily approaches the transition metal complex in terms of structure and a pentagon ring structure of the transition metal complex is stably maintained. The catalyst composition including the transition metal complex is used to synthesize a polyolefin copolymer having a very low density less than 0.910 g/cc.

Abstract: Provided are a novel transition metal complex where a monocyclopentadienyl ligand to which an amine-based group is introduced is coordinated, a method of synthesizing the same, and olefin polymerization using the transition metal complex In the novel transition metal complex, an imino phenyl group is not cross-linked to a metal atom and directly introduced to a cyclopentadiene (Cp) ring. The catalyst composition including the transition metal compound is used to obtain a polyolefin copolymer having a very low density less than 0.910 g/cc.